Cargando…

Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen

From 2009, Candida auris has emerged as a multidrug‐resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsiste...

Descripción completa

Detalles Bibliográficos
Autor principal: Osei Sekyere, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079168/
https://www.ncbi.nlm.nih.gov/pubmed/29345117
http://dx.doi.org/10.1002/mbo3.578
_version_ 1783345213791535104
author Osei Sekyere, John
author_facet Osei Sekyere, John
author_sort Osei Sekyere, John
collection PubMed
description From 2009, Candida auris has emerged as a multidrug‐resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsistencies in susceptibility testing results, misidentification by available commercial identification systems and treatment failure, complicates its management and detection. Within the last nine years, C. auris has been increasingly reported from far‐Eastern Asia, the Middle East, Africa, Europe, South and North America with substantial fatalities and misidentification. Herein, I provide a systematic and thorough review of this emerging pathogen. Meta‐analysis showed that at least 742 C. auris isolates have been reported in 16 countries, with most of these being from India (≥243), USA (≥232) and UK (≥103) (p‐value = .0355) within 2013–2017. Most isolates were from males (64.76%) (p‐value = .0329) and blood (67.48%) (p‐value < .0001), with substantial crude mortality (29.75%) (p‐value = .0488). Affected patients presented with other comorbidities: diabetes (≥52), sepsis (≥48), lung diseases (≥39), kidney diseases (≥32) etc. (p‐value < .0001). Resistance to fluconazole (44.29%), amphotericin B (15.46%), voriconazole (12.67%), caspofungin (3.48%) etc. were common (p‐value = .0059). Commonly used diagnostic tools included PCR (30.38%), Bruker MALDI‐TOF MS (14.00%), Vitek 2 YST ID (11.93%), AFLP (11.55%) and WGS (10.04%) (p‐value = .002). Multidrug resistance, high attributable mortality and persistence are associated with C. auris infections. Two novel drugs, SCY‐078 and VT‐1598, are currently in the pipeline. Contact precautions, strict infection control, periodic surveillance and cleaning with chlorine‐based detergents, efficient, faster and cheaper detection tools are necessary for prevention, containment and early diagnosis of C. auris infections.
format Online
Article
Text
id pubmed-6079168
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60791682018-08-09 Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen Osei Sekyere, John Microbiologyopen Original Research From 2009, Candida auris has emerged as a multidrug‐resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsistencies in susceptibility testing results, misidentification by available commercial identification systems and treatment failure, complicates its management and detection. Within the last nine years, C. auris has been increasingly reported from far‐Eastern Asia, the Middle East, Africa, Europe, South and North America with substantial fatalities and misidentification. Herein, I provide a systematic and thorough review of this emerging pathogen. Meta‐analysis showed that at least 742 C. auris isolates have been reported in 16 countries, with most of these being from India (≥243), USA (≥232) and UK (≥103) (p‐value = .0355) within 2013–2017. Most isolates were from males (64.76%) (p‐value = .0329) and blood (67.48%) (p‐value < .0001), with substantial crude mortality (29.75%) (p‐value = .0488). Affected patients presented with other comorbidities: diabetes (≥52), sepsis (≥48), lung diseases (≥39), kidney diseases (≥32) etc. (p‐value < .0001). Resistance to fluconazole (44.29%), amphotericin B (15.46%), voriconazole (12.67%), caspofungin (3.48%) etc. were common (p‐value = .0059). Commonly used diagnostic tools included PCR (30.38%), Bruker MALDI‐TOF MS (14.00%), Vitek 2 YST ID (11.93%), AFLP (11.55%) and WGS (10.04%) (p‐value = .002). Multidrug resistance, high attributable mortality and persistence are associated with C. auris infections. Two novel drugs, SCY‐078 and VT‐1598, are currently in the pipeline. Contact precautions, strict infection control, periodic surveillance and cleaning with chlorine‐based detergents, efficient, faster and cheaper detection tools are necessary for prevention, containment and early diagnosis of C. auris infections. John Wiley and Sons Inc. 2018-01-18 /pmc/articles/PMC6079168/ /pubmed/29345117 http://dx.doi.org/10.1002/mbo3.578 Text en © 2018 The Author. MicrobiologyOpen published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Osei Sekyere, John
Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title_full Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title_fullStr Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title_full_unstemmed Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title_short Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
title_sort candida auris: a systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079168/
https://www.ncbi.nlm.nih.gov/pubmed/29345117
http://dx.doi.org/10.1002/mbo3.578
work_keys_str_mv AT oseisekyerejohn candidaaurisasystematicreviewandmetaanalysisofcurrentupdatesonanemergingmultidrugresistantpathogen